Results- Financial Results for March 31,2 026
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Ltd reported a net loss of Rs 487 million for FY2026, a sharp reversal from net profit of Rs 909 million in FY2025. Total revenue declined 7.9% to Rs 17,126 million from Rs 18,598 million, driven by a 12.6% fall in the Pharmaceuticals segment (to Rs 10,210 million) following a USFDA warning letter for its Jigani facility. Two material exceptional items weighed on results: an impairment charge of Rs 471 million for assets at a repurposed manufacturing plant, and Rs 380 million in employee benefit costs from new Indian labour codes (gratuity and compensated absences). PBT before exceptional items fell to just Rs 69 million from Rs 1,239 million. The company declared a total dividend of 30% (Rs 0.60 per share), down from 70% (Rs 1.40) the prior year. Operating cash flow remained healthy at Rs 3,021 million. The auditors issued an unmodified opinion but included an Emphasis of Matter on ongoing environmental law proceedings pending before the Supreme Court. Total assets declined to Rs 23,654 million from Rs 25,291 million.
The sharp swing to a net loss, revenue decline, and exceptional charges signal serious earnings pressure, likely causing negative sentiment. However, the unmodified auditor opinion and strong operating cash flow provide some comfort, while the unresolved USFDA and environmental issues remain key risks.